RVTY has put in one of its strongest weekly performances in recent memory — up 15.4% to $143.45 — yet analyst targets haven't kept pace, and the options market is the least defensive it's been in months.
The most striking tension this week is the gap between price and analyst conviction. UBS assumed coverage on September 9 at Neutral with a $140 target — a price the stock has already blown through. Keybanc was more constructive, raising its target to $165 while maintaining Overweight on September 4, which now looks like the only Street call with meaningful room above current levels. RBC initiated at Sector Perform with a $135 target on September 1, already underwater. The consensus sits at Hold with no Buy majority in sight, and most recent targets cluster well below $143. The Street is not positioned for where the stock currently trades.
Options traders, meanwhile, are leaning bullish rather than cautious — which is notable given how far the stock has moved. The put/call ratio is running at 0.58, nearly a full standard deviation below its 20-day average of 0.67. That's toward the low end of recent readings and suggests options participants are reaching for upside rather than hedging gains. The bull case from Benzinga centres on margin expansion in Life Science Solutions and the Signals platform driving incremental growth. Bears point to currency exposure, dependence on volatile biopharma funding cycles, and declining birth rates pressuring the Reproductive Health business — risks that don't disappear just because the stock has rallied 26% over the past month.
Short interest tells an unexcited story on the other side. Bears have been cutting exposure for weeks — SI as a percentage of free float has eased from roughly 6.3% at the start of September to 5.6% now, a six-week low. The borrow market is loose: availability is running at 432%, well into normal territory, and cost to borrow is a negligible 0.50%. There is no squeeze pressure here and no sign that remaining shorts are under stress. The ORTEX short score has drifted down from 51.8 on September 7 to 49.3 this week, confirming the trend — short conviction is fading, not building.
Institutional ownership adds an interesting wrinkle. T. Rowe Price is the dominant holder at roughly 14% of shares, but its two separate 13G filings tell a more nuanced story: T. Rowe Price Associates cut from 9% to 5% of class in August, while T. Rowe Price Investment Management trimmed even more sharply — from 16.4% to 9.2% — in a filing dated September 8. Both positions remain above the 5% disclosure threshold, so further reductions may happen without triggering a new filing. EdgePoint Investment Group has been moving the other way, lifting its stake from 5.76% to 7.39% as of November 2025 disclosures. These 13D/G positions are event-driven disclosures around the 5% threshold and are as last disclosed — the picture may have shifted since.
On a one-week basis, RVTY's 15.4% gain has outpaced close peers meaningfully. TMO rose 6.8% and RGEN gained 7.1%, while WAT managed only 3.3% and CRL was essentially flat. The forward EPS growth factor score — in the 96th percentile of the universe — and a P/E that has expanded roughly 4.6 points over the past month to around 25.6x suggest the market is pricing in a recovery that the consensus hasn't yet endorsed.
The next formal test arrives on November 5, when Revvity reports Q3 results. After its August print the stock barely moved on the day but recovered 0.4% over the following five sessions — a muted reaction in either direction. With the stock now trading above every major analyst target except Keybanc's $165, the question heading into that print is whether the fundamental case can catch up with a price that has already done a lot of the work.
See the live data behind this article on ORTEX.
Open RVTY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
